首页 > 最新文献

World Journal of Nuclear Medicine最新文献

英文 中文
Prostate Cancer Skeletal Metastasis: A Spontaneous Evolution from Osteolytic to Osteoblastic Morphology without Treatment. 前列腺癌骨骼转移:无需治疗即可从溶骨形态自发演变为成骨形态。
IF 0.6 Pub Date : 2023-12-26 eCollection Date: 2023-12-01 DOI: 10.1055/s-0043-1777697
Ismaheel O Lawal, Mehmet A Bilen, Raghuveer K Halkar, Ashesh B Jani, David M Schuster

Skeletal metastases due to prostate cancer (PCa) are more commonly osteoblastic than osteolytic. In the rarer cases of osteolytic skeletal metastasis of PCa, transition to osteoblastic phenotype occurs following treatment, which indicates successful healing. In this report, we present a case of spontaneous osteolytic to osteoblastic evolution of PCa skeletal metastasis without treatment in a patient with recurrence of PCa. Our patient is a 59-year-old male who had a robotic radical prostatectomy in July 2014 for a T2c adenocarcinoma of the prostate gland (Gleason score = 4 + 3). He had adjuvant pelvic radiotherapy in January 2015 due to prostate-specific antigen (PSA) persistence. PSA began to rise in October 2015. An 18 F-fluciclovine positron emission tomography/computed tomography (PET/CT) scan obtained in June 2017 at a PSA of 0.5 ng/mL was negative. Repeat 18 F-fluciclovine PET/CT of February 2020 at PSA of 3.72 ng/mL showed prostate bed recurrence and a nonavid osteolytic left inferior pubic ramus lesion. 18F radiohybrid prostate-specific membrane antigen ( 18 F-rhPSMA) PET/CT scan of August 2020 performed as part of an ongoing clinical trial confirmed local prostate bed recurrence with a low-grade radiotracer uptake in the osteolytic left inferior pubic ramus bone lesion. Without salvage therapy, 18 F-fluciclovine PET/CT of October 2020 and March 2022 shows progressive sclerosis in the left pubic ramus lesion. An osteolytic to osteoblastic transition of a bone lesion as shown in this patient calls for a rethink in our understanding of untreated PCa skeletal metastasis progression. This case provides novel insight into the understanding of the temporal evolution of skeletal metastasis and calls for further research.

前列腺癌(PCa)引起的骨骼转移多为成骨性而非溶骨性。在较罕见的 PCa 溶骨性骨骼转移病例中,治疗后会出现向成骨细胞表型的转变,这表明愈合成功。在本报告中,我们介绍了一例PCa骨骼转移瘤在未接受治疗的情况下自发由溶骨型向成骨型演变的病例。患者是一名59岁的男性,2014年7月因前列腺T2c腺癌(格里森评分=4+3)接受了机器人前列腺癌根治术。由于前列腺特异性抗原(PSA)持续存在,他于2015年1月接受了盆腔辅助放疗。2015年10月,PSA开始上升。2017 年 6 月 PSA 为 0.5 纳克/毫升时,进行了 18 F-氟西曲吠陀正电子发射断层扫描/计算机断层扫描(PET/CT),结果为阴性。2020 年 2 月,在 PSA 为 3.72 纳克/毫升时再次进行的 18F- 葡萄球菌正电子发射断层扫描/计算机断层扫描显示前列腺床复发和非avid 溶骨性左耻骨下横突病变。作为正在进行的临床试验的一部分,2020 年 8 月进行的 18F 放射杂交前列腺特异性膜抗原(18 F-rhPSMA)PET/CT 扫描证实前列腺局部复发,左耻骨下横突骨溶骨性病变有低度放射性示踪剂摄取。在未进行挽救性治疗的情况下,2020 年 10 月和 2022 年 3 月的 18 F- 氟西酞胺 PET/CT 显示左耻骨下横突骨病变呈进行性硬化。该患者的骨病变由溶骨性向成骨性转变,这要求我们重新认识未经治疗的 PCa 骨骼转移进展。该病例为我们了解骨骼转移的时间演变提供了新的视角,需要进一步研究。
{"title":"Prostate Cancer Skeletal Metastasis: A Spontaneous Evolution from Osteolytic to Osteoblastic Morphology without Treatment.","authors":"Ismaheel O Lawal, Mehmet A Bilen, Raghuveer K Halkar, Ashesh B Jani, David M Schuster","doi":"10.1055/s-0043-1777697","DOIUrl":"10.1055/s-0043-1777697","url":null,"abstract":"<p><p>Skeletal metastases due to prostate cancer (PCa) are more commonly osteoblastic than osteolytic. In the rarer cases of osteolytic skeletal metastasis of PCa, transition to osteoblastic phenotype occurs following treatment, which indicates successful healing. In this report, we present a case of spontaneous osteolytic to osteoblastic evolution of PCa skeletal metastasis without treatment in a patient with recurrence of PCa. Our patient is a 59-year-old male who had a robotic radical prostatectomy in July 2014 for a T2c adenocarcinoma of the prostate gland (Gleason score = 4 + 3). He had adjuvant pelvic radiotherapy in January 2015 due to prostate-specific antigen (PSA) persistence. PSA began to rise in October 2015. An <sup>18</sup> F-fluciclovine positron emission tomography/computed tomography (PET/CT) scan obtained in June 2017 at a PSA of 0.5 ng/mL was negative. Repeat <sup>18</sup> F-fluciclovine PET/CT of February 2020 at PSA of 3.72 ng/mL showed prostate bed recurrence and a nonavid osteolytic left inferior pubic ramus lesion. 18F radiohybrid prostate-specific membrane antigen ( <sup>18</sup> F-rhPSMA) PET/CT scan of August 2020 performed as part of an ongoing clinical trial confirmed local prostate bed recurrence with a low-grade radiotracer uptake in the osteolytic left inferior pubic ramus bone lesion. Without salvage therapy, <sup>18</sup> F-fluciclovine PET/CT of October 2020 and March 2022 shows progressive sclerosis in the left pubic ramus lesion. An osteolytic to osteoblastic transition of a bone lesion as shown in this patient calls for a rethink in our understanding of untreated PCa skeletal metastasis progression. This case provides novel insight into the understanding of the temporal evolution of skeletal metastasis and calls for further research.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Middle Ear Cavity and Mastoid Neuroendocrine Tumor Presenting as Otomastoiditis with Cholesteatoma: A Clinicoradiological and Histopathological Correlation. 中耳腔和乳突神经内分泌瘤表现为胆脂瘤性耳炎:临床放射学和组织病理学相关性研究。
IF 0.6 Pub Date : 2023-12-26 eCollection Date: 2023-12-01 DOI: 10.1055/s-0043-1777695
Ashwini Chalikandy, Sandip Basu

Neuroendocrine tumors of the middle ear are rare, comprising of less than 2% of primary tumors of the ear. The clinical and imaging findings of these tumors are nonspecific, and histological and immunohistochemical findings are confirmatory. Herein, we present a case of 48-year-old male, presenting with chief complaints of hearing loss of left ear with foul smelling discharge, with the initial clinical impression of otomastoiditis of the middle ear with cholesteatoma and being operated for the same, the final histopathology report inferred it as well-differentiated neuroendocrine tumor grade 1 with Ki-67 index less than 2%. Immunohistochemical examinations demonstrated positive staining of the tumor cells for cytokeratin, synaptophysin and chromogranin A, and negative for smooth muscle actin, desmin, S-100. The biochemical investigations showed raised serum chromogranin A levels. Based upon the findings on anatomical imaging modalities including high-resolution computed tomography temporal bone and magnetic resonance imaging paranasal sinuses (MRI PNS), the lesion was inferred inoperable due to involvement of dura of petrous apex, and therefore he was referred for consideration of peptide receptor radionuclide therapy (PRRT). MRI PNS also showed involvement of the horizontal part of facial nerve, indicating local aggressiveness of the tumor. 68 Ga-DOTATATE-PET/CT showed high-grade somatostatin receptor expressing soft tissue lesion involving middle ear and external auditory canal (Krenning's score 4), with low-grade metabolic activity on 18 F-FDG-PET/CT. The post-therapy scan following 177 Lu-DOTATATE PRRT, showed abnormal tracer concentration at the described site. Due to extreme rarity of this disease entity, it is important to accrue data for accurate diagnosis, proper management, and follow-up.

中耳神经内分泌肿瘤十分罕见,在耳部原发性肿瘤中所占比例不到 2%。这些肿瘤的临床和影像学检查结果无特异性,组织学和免疫组化检查结果才能确诊。在此,我们介绍一例 48 岁男性病例,主诉为左耳听力下降并伴有恶臭分泌物,初步临床印象为中耳炎伴胆脂瘤,并为此进行了手术,最终组织病理报告推断为分化良好的神经内分泌肿瘤 1 级,Ki-67 指数小于 2%。免疫组化检查显示,肿瘤细胞的细胞角蛋白、突触素和嗜铬粒蛋白 A 染色阳性,平滑肌肌动蛋白、desmin 和 S-100 阴性。生化检查显示血清嗜铬粒蛋白 A 水平升高。根据颞骨高分辨率计算机断层扫描和副鼻窦磁共振成像(MRI PNS)等解剖成像模式的检查结果,推断该病变因累及岩顶硬脑膜而无法手术,因此他被转诊考虑接受肽受体放射性核素治疗(PRRT)。MRI PNS还显示面神经水平部分受累,表明肿瘤具有局部侵袭性。68 Ga-DOTATATE-PET/CT显示高级别体生长抑素受体表达的软组织病变累及中耳和外耳道(Krenning评分4分),18 F-FDG-PET/CT显示低级别代谢活动。177 Lu-DOTATATE PRRT治疗后扫描显示,上述部位的示踪剂浓度异常。由于这种疾病极为罕见,因此积累数据对于准确诊断、正确治疗和随访非常重要。
{"title":"Middle Ear Cavity and Mastoid Neuroendocrine Tumor Presenting as Otomastoiditis with Cholesteatoma: A Clinicoradiological and Histopathological Correlation.","authors":"Ashwini Chalikandy, Sandip Basu","doi":"10.1055/s-0043-1777695","DOIUrl":"10.1055/s-0043-1777695","url":null,"abstract":"<p><p>Neuroendocrine tumors of the middle ear are rare, comprising of less than 2% of primary tumors of the ear. The clinical and imaging findings of these tumors are nonspecific, and histological and immunohistochemical findings are confirmatory. Herein, we present a case of 48-year-old male, presenting with chief complaints of hearing loss of left ear with foul smelling discharge, with the initial clinical impression of otomastoiditis of the middle ear with cholesteatoma and being operated for the same, the final histopathology report inferred it as well-differentiated neuroendocrine tumor grade 1 with Ki-67 index less than 2%. Immunohistochemical examinations demonstrated positive staining of the tumor cells for cytokeratin, synaptophysin and chromogranin A, and negative for smooth muscle actin, desmin, S-100. The biochemical investigations showed raised serum chromogranin A levels. Based upon the findings on anatomical imaging modalities including high-resolution computed tomography temporal bone and magnetic resonance imaging paranasal sinuses (MRI PNS), the lesion was inferred inoperable due to involvement of dura of petrous apex, and therefore he was referred for consideration of peptide receptor radionuclide therapy (PRRT). MRI PNS also showed involvement of the horizontal part of facial nerve, indicating local aggressiveness of the tumor. <sup>68</sup> Ga-DOTATATE-PET/CT showed high-grade somatostatin receptor expressing soft tissue lesion involving middle ear and external auditory canal (Krenning's score 4), with low-grade metabolic activity on <sup>18</sup> F-FDG-PET/CT. The post-therapy scan following <sup>177</sup> Lu-DOTATATE PRRT, showed abnormal tracer concentration at the described site. Due to extreme rarity of this disease entity, it is important to accrue data for accurate diagnosis, proper management, and follow-up.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of Bilateral SLN Radiocolloid Detection in Endometrial Carcinoma. 子宫内膜癌双侧 SLN 放射性胶体检测的预测因素
IF 0.6 Pub Date : 2023-12-26 eCollection Date: 2023-12-01 DOI: 10.1055/s-0043-1777693
Anamarija Jankulovska, Sasho Stojcevski, Igor Aluloski, Mile Tanturovski, Nevena Manevska, Ana Daneva Markova, Sinisa Stojanoski

Introduction  Sentinel lymph node (SLN) mapping is an alternative method to conventional lymphadenectomy for nodal status assessment in patients with stage I/II endometrial carcinoma (EC). This study aimed to analyze the potential predictors of unsuccessful bilateral detection of SLN after the application of radiocolloid in EC. Materials and Methods  A prospective, observational, cross-sectional study was performed on 41 patients with EC in preoperative stage I, who underwent SLN mapping after cervical application of 4mCi 99m Tc-SENTI-SCINT. The demographic, clinical, and tumor-related data were obtained from the patient's medical records. Univariate analysis was used to analyze the potential factors associated with an unsuccessful bilateral SLN biopsy. Results  The bilateral SLN detection rate of planar lymphoscintigraphy, single photon emission computed tomography/computed tomography, and gamma probe was 29.26, 41.46, and 26.82%, correspondingly. None of the 16 analyzed risk factors showed statistical significance for nonconclusive bilateral SLN biopsy. Conclusion  Larger scale studies are needed to determine the exact risk factors for unsuccessful bilateral mapping of the lymphatic drainage after cervical application of the radiotracers. This will eventually lead to improvement in bilateral SLN detection in EC patients, so unilateral lymphadenectomy could be avoided.

导言前哨淋巴结(SLN)绘图是 I/II 期子宫内膜癌(EC)患者进行结节状态评估时传统淋巴结切除术的替代方法。本研究旨在分析子宫内膜癌患者应用放射性胶体后双侧SLN检测不成功的潜在预测因素。材料与方法 对 41 例术前处于 I 期的 EC 患者进行了前瞻性、观察性、横断面研究,这些患者在宫颈应用 4mCi 99m Tc-SENTI-SCINT 后接受了 SLN 测绘。人口统计学、临床和肿瘤相关数据均来自患者的病历。单变量分析用于分析与双侧 SLN 活检不成功相关的潜在因素。结果 平面淋巴管造影、单光子发射计算机断层扫描/计算机断层扫描和伽马探针的双侧 SLN 检出率分别为 29.26%、41.46% 和 26.82%。在分析的 16 个风险因素中,没有一个因素对双侧 SLN 活检不确诊有统计学意义。结论 需要进行更大规模的研究,以确定颈部应用放射性核素后双侧淋巴引流图绘制不成功的确切风险因素。这将最终改善心血管疾病患者的双侧 SLN 检测,从而避免单侧淋巴结切除术。
{"title":"Predictors of Bilateral SLN Radiocolloid Detection in Endometrial Carcinoma.","authors":"Anamarija Jankulovska, Sasho Stojcevski, Igor Aluloski, Mile Tanturovski, Nevena Manevska, Ana Daneva Markova, Sinisa Stojanoski","doi":"10.1055/s-0043-1777693","DOIUrl":"10.1055/s-0043-1777693","url":null,"abstract":"<p><p><b>Introduction</b>  Sentinel lymph node (SLN) mapping is an alternative method to conventional lymphadenectomy for nodal status assessment in patients with stage I/II endometrial carcinoma (EC). This study aimed to analyze the potential predictors of unsuccessful bilateral detection of SLN after the application of radiocolloid in EC. <b>Materials and Methods</b>  A prospective, observational, cross-sectional study was performed on 41 patients with EC in preoperative stage I, who underwent SLN mapping after cervical application of 4mCi <sup>99m</sup> Tc-SENTI-SCINT. The demographic, clinical, and tumor-related data were obtained from the patient's medical records. Univariate analysis was used to analyze the potential factors associated with an unsuccessful bilateral SLN biopsy. <b>Results</b>  The bilateral SLN detection rate of planar lymphoscintigraphy, single photon emission computed tomography/computed tomography, and gamma probe was 29.26, 41.46, and 26.82%, correspondingly. None of the 16 analyzed risk factors showed statistical significance for nonconclusive bilateral SLN biopsy. <b>Conclusion</b>  Larger scale studies are needed to determine the exact risk factors for unsuccessful bilateral mapping of the lymphatic drainage after cervical application of the radiotracers. This will eventually lead to improvement in bilateral SLN detection in EC patients, so unilateral lymphadenectomy could be avoided.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18 F-Fluorocholine PET-CT Outshines Sestamibi Scintigraphy in Detecting Parathyroid Adenomas in the Background of Hashimoto's Thyroiditis 18 F-氟胆碱PET-CT在检测桥本氏甲状腺炎背景下的甲状旁腺腺瘤方面优于胱胺比闪烁照相法
IF 0.6 Pub Date : 2023-12-04 DOI: 10.1055/s-0043-1774732
Piyush Chandra, Dipayan Nandy, Samir Saini
Abstract Ultrasonography neck and dual-phase 99m Tc-sestamibi (MIBI) scan are standard imaging techniques for the detection of parathyroid adenomas in primary hyperparathyroidism. However, in presence of coexistent thyroid disease or small size of adenomas, the accuracy of these imaging modalities is low and leads to delayed diagnosis. We here present a report of two patients with primary hyperparathyroidism and with a nondiagnostic MIBI scan, who subsequently underwent successful surgery after positive localization of adenomas on 18 F-fluorocholine positron emission tomography-computed tomography.
颈部超声和双期99m Tc-sestamibi (MIBI)扫描是原发性甲状旁腺功能亢进患者检测甲状旁腺瘤的标准成像技术。然而,当存在共存的甲状腺疾病或小尺寸腺瘤时,这些成像方式的准确性较低,导致诊断延迟。我们在此报告了两例原发性甲状旁腺功能亢进和非诊断性MIBI扫描的患者,他们随后在18f -氟胆碱正电子发射断层扫描-计算机断层扫描上腺瘤定位阳性后接受了成功的手术。
{"title":"18 F-Fluorocholine PET-CT Outshines Sestamibi Scintigraphy in Detecting Parathyroid Adenomas in the Background of Hashimoto's Thyroiditis","authors":"Piyush Chandra, Dipayan Nandy, Samir Saini","doi":"10.1055/s-0043-1774732","DOIUrl":"https://doi.org/10.1055/s-0043-1774732","url":null,"abstract":"Abstract Ultrasonography neck and dual-phase 99m Tc-sestamibi (MIBI) scan are standard imaging techniques for the detection of parathyroid adenomas in primary hyperparathyroidism. However, in presence of coexistent thyroid disease or small size of adenomas, the accuracy of these imaging modalities is low and leads to delayed diagnosis. We here present a report of two patients with primary hyperparathyroidism and with a nondiagnostic MIBI scan, who subsequently underwent successful surgery after positive localization of adenomas on 18 F-fluorocholine positron emission tomography-computed tomography.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138604001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Radioactive Iodine Treatment Affects the Retina 放射性碘治疗如何影响视网膜
IF 0.6 Pub Date : 2023-12-04 DOI: 10.1055/s-0043-1774419
Ceren Gürez, Aynur Özen, Özgül Ekmekçioğlu
Abstract Objective  The aim of this study was to quantitatively assess the macular and retinal nerve fiber layer thicknesses in patients with hyperthyroidism and thyroid cancer undergoing radioactive iodine (RAI) therapy. Study Design  This prospective study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Bagcilar Training and Research Hospital Clinical Research Ethics Committee. Written informed consent was obtained from the patients following a detailed explanation of the study objectives and protocol. Patient selection was randomized. Patients scheduled for RAI treatment in the Nuclear Medicine Clinic were referred to the ophthalmology clinic, respectively. Patients without additional ocular pathology were included in the study. Methods  All patients had received RAI therapy using Iodine-131 for hyperthyroidism or thyroid cancer. A complete ophthalmological examination and measurement of macular and retinal nerve fiber layer thickness using optical coherence tomography were performed on all patients before and at the first and sixth months and in first year after RAI treatment. The results were prospectively evaluated. Results  The study included 80 eyes of 40 patients. The hyperthyroid group was group 1, and the thyroid cancer group was group 2. There were 25 patients in group 1 and 15 patients in group 2. The mean age was 43.76 ± 11.85 years (range: 22–65 years) in group 1 and 39.87 ± 9.13 years (range: 30–58 years) in group 2. There was no significant difference between the two groups regarding age and sex ( p  > 0.05). In both groups, no significant difference was found in the macular thickness and retinal nerve fiber layer thicknesses values obtained in both eyes before and after the RAI treatment. Conclusion  As a result of our study, we observed that RAI intake did not harm the retinal layer.
摘要目的定量评价甲状腺机能亢进和甲状腺癌患者接受放射性碘(RAI)治疗后黄斑和视网膜神经纤维层厚度。研究设计本前瞻性研究按照赫尔辛基宣言的原则进行,并经Bagcilar培训与研究医院临床研究伦理委员会批准。在详细解释研究目标和方案后,获得患者的书面知情同意。患者的选择是随机的。原计划在核医学诊所接受RAI治疗的患者分别转至眼科诊所。无其他眼部病理的患者被纳入研究。方法对甲状腺功能亢进或甲状腺癌患者均采用碘-131放射治疗。所有患者在RAI治疗前、第1个月和第6个月以及治疗后的第一年进行了完整的眼科检查和使用光学相干断层扫描测量黄斑和视网膜神经纤维层厚度。对结果进行前瞻性评价。结果共纳入40例患者80只眼。甲状腺功能亢进组为1组,甲状腺癌组为2组。1组25例,2组15例。1组患者平均年龄43.76±11.85岁(范围22 ~ 65岁),2组患者平均年龄39.87±9.13岁(范围30 ~ 58岁)。两组患者年龄、性别差异无统计学意义(p > 0.05)。两组患者RAI治疗前后双眼黄斑厚度及视网膜神经纤维层厚度值均无显著差异。结论本研究观察到RAI摄入对视网膜层无损伤。
{"title":"How Radioactive Iodine Treatment Affects the Retina","authors":"Ceren Gürez, Aynur Özen, Özgül Ekmekçioğlu","doi":"10.1055/s-0043-1774419","DOIUrl":"https://doi.org/10.1055/s-0043-1774419","url":null,"abstract":"Abstract Objective  The aim of this study was to quantitatively assess the macular and retinal nerve fiber layer thicknesses in patients with hyperthyroidism and thyroid cancer undergoing radioactive iodine (RAI) therapy. Study Design  This prospective study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Bagcilar Training and Research Hospital Clinical Research Ethics Committee. Written informed consent was obtained from the patients following a detailed explanation of the study objectives and protocol. Patient selection was randomized. Patients scheduled for RAI treatment in the Nuclear Medicine Clinic were referred to the ophthalmology clinic, respectively. Patients without additional ocular pathology were included in the study. Methods  All patients had received RAI therapy using Iodine-131 for hyperthyroidism or thyroid cancer. A complete ophthalmological examination and measurement of macular and retinal nerve fiber layer thickness using optical coherence tomography were performed on all patients before and at the first and sixth months and in first year after RAI treatment. The results were prospectively evaluated. Results  The study included 80 eyes of 40 patients. The hyperthyroid group was group 1, and the thyroid cancer group was group 2. There were 25 patients in group 1 and 15 patients in group 2. The mean age was 43.76 ± 11.85 years (range: 22–65 years) in group 1 and 39.87 ± 9.13 years (range: 30–58 years) in group 2. There was no significant difference between the two groups regarding age and sex ( p  > 0.05). In both groups, no significant difference was found in the macular thickness and retinal nerve fiber layer thicknesses values obtained in both eyes before and after the RAI treatment. Conclusion  As a result of our study, we observed that RAI intake did not harm the retinal layer.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138604849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT 通过 FDG PET/CT 检测到恶性胸膜间皮瘤的广泛骨骼肌转移
IF 0.6 Pub Date : 2023-12-04 DOI: 10.1055/s-0043-1774730
Mustafa Yilmaz, Ozan Kandemir, Ediz Tutar
Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from pleural mesothelial cells. Distant skeletal muscle metastasis is rare in MPM. A 54-year-old woman was diagnosed with epithelioid MPM and treated with surgery, chemotherapy, and radiotherapy 2 years ago. During follow-up, diffuse irregular pleural thickening with focal chest wall invasion in the right hemithorax and two small pleural thickenings in the left hemithorax were seen on control diagnostic contrast-enhanced computed tomography (CECT). Fluorine-18 fluorodeoxyglucose positron emission tomography/CT (FDG PET/CT) imaging was performed as part of restaging. PET showed diffusely increased FDG uptake in the recurrent right pleural tumor, and two hypermetabolic small metastatic foci in the contralateral pleura. In addition, multiple hypermetabolic areas of various sizes in various skeletal muscle localizations, suggestive of extensive muscle metastases were noted. Histopathologic study confirmed metastatic epithelioid MPM. FDG PET/CT revealed multiple muscle metastases which were not observed on earlier CECT and contributed to the visualization of more extensive metastatic involvements in the presented case with MPM. FDG PET/CT can detect rarely seen skeletal muscle metastases that are not visualized on diagnostic CT, and provides more accurate restaging of MPM.
摘要恶性胸膜间皮瘤是一种罕见但侵袭性的肿瘤,起源于胸膜间皮瘤细胞。远端骨骼肌转移在MPM中很少见。一名54岁女性2年前被诊断为上皮样MPM,并接受了手术、化疗和放疗。在随访期间,在对照诊断性增强计算机断层扫描(CECT)上发现右半胸弥漫性不规则胸膜增厚伴局灶性胸壁浸润,左半胸两处小胸膜增厚。氟-18氟脱氧葡萄糖正电子发射断层扫描/CT (FDG PET/CT)成像作为再分期的一部分。PET显示复发性右胸膜肿瘤中FDG摄取弥漫性增加,对侧胸膜中有两个高代谢小转移灶。此外,在不同的骨骼肌部位发现多个不同大小的高代谢区域,提示广泛的肌肉转移。组织病理学检查证实为转移性上皮样MPM。FDG PET/CT显示了早期CECT未观察到的多发肌肉转移,并有助于在本病例中显示更广泛的转移灶。FDG PET/CT可以发现诊断CT上未见的罕见骨骼肌转移,并提供更准确的MPM重新定位。
{"title":"Extensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT","authors":"Mustafa Yilmaz, Ozan Kandemir, Ediz Tutar","doi":"10.1055/s-0043-1774730","DOIUrl":"https://doi.org/10.1055/s-0043-1774730","url":null,"abstract":"Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from pleural mesothelial cells. Distant skeletal muscle metastasis is rare in MPM. A 54-year-old woman was diagnosed with epithelioid MPM and treated with surgery, chemotherapy, and radiotherapy 2 years ago. During follow-up, diffuse irregular pleural thickening with focal chest wall invasion in the right hemithorax and two small pleural thickenings in the left hemithorax were seen on control diagnostic contrast-enhanced computed tomography (CECT). Fluorine-18 fluorodeoxyglucose positron emission tomography/CT (FDG PET/CT) imaging was performed as part of restaging. PET showed diffusely increased FDG uptake in the recurrent right pleural tumor, and two hypermetabolic small metastatic foci in the contralateral pleura. In addition, multiple hypermetabolic areas of various sizes in various skeletal muscle localizations, suggestive of extensive muscle metastases were noted. Histopathologic study confirmed metastatic epithelioid MPM. FDG PET/CT revealed multiple muscle metastases which were not observed on earlier CECT and contributed to the visualization of more extensive metastatic involvements in the presented case with MPM. FDG PET/CT can detect rarely seen skeletal muscle metastases that are not visualized on diagnostic CT, and provides more accurate restaging of MPM.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138604913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pros and Cons of Alpha versus Beta Bone Seeking Agents in the Treatment of Cancer Pain 治疗癌症疼痛的阿尔法骨质疏松剂与贝塔骨质疏松剂的利与弊
IF 0.6 Pub Date : 2023-12-04 DOI: 10.1055/s-0043-1774731
K. Liepe
Skeletal metastases occur in many types of solid malignant tumors, especially in advanced stage of prostate, breast, and lung cancers. The resulting bone pain affects patient ’ s quality of life and requires effective treatment. Only osteoblastic bone metastases are suitable for treatment with bone-seeking agents. Typical tumors are prostate cancer with 65 to 85% of bone metastases, breast cancer with 65 to 75%, and small cell lung cancer with 34 to 50%, respectively. 1 The mechanisms involved in bone pain are poorly understood, 2 but are likely to be a consequence of osteolysis (bone breakdown). 3 In fi ltration of the bone trabeculae and matrix by tumor osteolysis is one of the physical factors. Pain may result from instability-based microfractures and stretching of the periosteum by tumor growth. 4 The pathophysiological mechanisms of pain include stimulation of free nerve endings in the endosteum bya variety ofchemical mediators like bradykinin,prostaglandin, histamine, interleukin, and tumor necrosis factor. 4,5
骨骼转移发生在许多类型的实体恶性肿瘤中,尤其是晚期前列腺癌、乳腺癌和肺癌。由此产生的骨痛影响患者的生活质量,需要有效的治疗。只有成骨细胞骨转移适合用寻骨剂治疗。典型的肿瘤是前列腺癌,骨转移率为65 ~ 85%,乳腺癌为65 ~ 75%,小细胞肺癌为34 ~ 50%。1骨痛的机制尚不清楚,2但可能是骨溶解(骨破坏)的结果。肿瘤溶骨对骨小梁和骨基质的滤过是物理因素之一。疼痛可能是由不稳定的微骨折和肿瘤生长引起的骨膜拉伸引起的。疼痛的病理生理机制包括各种化学介质如缓激肽、前列腺素、组胺、白细胞介素和肿瘤坏死因子对内皮自由神经末梢的刺激。4、5
{"title":"Pros and Cons of Alpha versus Beta Bone Seeking Agents in the Treatment of Cancer Pain","authors":"K. Liepe","doi":"10.1055/s-0043-1774731","DOIUrl":"https://doi.org/10.1055/s-0043-1774731","url":null,"abstract":"Skeletal metastases occur in many types of solid malignant tumors, especially in advanced stage of prostate, breast, and lung cancers. The resulting bone pain affects patient ’ s quality of life and requires effective treatment. Only osteoblastic bone metastases are suitable for treatment with bone-seeking agents. Typical tumors are prostate cancer with 65 to 85% of bone metastases, breast cancer with 65 to 75%, and small cell lung cancer with 34 to 50%, respectively. 1 The mechanisms involved in bone pain are poorly understood, 2 but are likely to be a consequence of osteolysis (bone breakdown). 3 In fi ltration of the bone trabeculae and matrix by tumor osteolysis is one of the physical factors. Pain may result from instability-based microfractures and stretching of the periosteum by tumor growth. 4 The pathophysiological mechanisms of pain include stimulation of free nerve endings in the endosteum bya variety ofchemical mediators like bradykinin,prostaglandin, histamine, interleukin, and tumor necrosis factor. 4,5","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138601610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDG PET-CT in Clinical Management of a Rare Case of Primary Hepatic Lymphoma: Role and Challenges FDG PET-CT 在罕见原发性肝淋巴瘤临床治疗中的作用与挑战作用与挑战
IF 0.6 Pub Date : 2023-12-04 DOI: 10.1055/s-0043-1774734
T. Jain, Naveen Gupta, Hemant Malhotra, Lalit Mohan Sharma
Abstract The common differential diagnoses for multiple space-occupying hepatic lesions (SOL) are metastases, multifocal hepatocellular carcinoma, and abscess. Primary hepatic lymphomas are rare entities that present many challenges with regard to their management. Fluorodeoxyglucose positron emission tomography-computed tomography is extensively used for the staging and response assessment of lymphomas but it can be challenging and difficult to interpret in cases with isolated liver involvement. We hereby present the case of an 82-year-old lady who presented with multiple liver SOL.
多发占位性肝病变(SOL)的常见鉴别诊断为转移、多灶性肝细胞癌和脓肿。原发性肝淋巴瘤是罕见的实体,提出了许多挑战,关于他们的管理。氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描广泛用于淋巴瘤的分期和反应评估,但在孤立肝脏受累的情况下,它可能具有挑战性和难以解释。我们在此报告一位82岁的女士,她表现出多发性肝脏SOL。
{"title":"FDG PET-CT in Clinical Management of a Rare Case of Primary Hepatic Lymphoma: Role and Challenges","authors":"T. Jain, Naveen Gupta, Hemant Malhotra, Lalit Mohan Sharma","doi":"10.1055/s-0043-1774734","DOIUrl":"https://doi.org/10.1055/s-0043-1774734","url":null,"abstract":"Abstract The common differential diagnoses for multiple space-occupying hepatic lesions (SOL) are metastases, multifocal hepatocellular carcinoma, and abscess. Primary hepatic lymphomas are rare entities that present many challenges with regard to their management. Fluorodeoxyglucose positron emission tomography-computed tomography is extensively used for the staging and response assessment of lymphomas but it can be challenging and difficult to interpret in cases with isolated liver involvement. We hereby present the case of an 82-year-old lady who presented with multiple liver SOL.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138603964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Familial MEN1 Syndrome Diagnosed on Functional Imaging: A Case Report with Clinical and Genetic Correlation 通过功能成像诊断的家族性 MEN1 综合征:与临床和遗传相关的病例报告
IF 0.6 Pub Date : 2023-12-04 DOI: 10.1055/s-0043-1768448
Ashwini Kalshetty, Ashwini Chalikandy
Abstract Multiple endocrine neoplasia, type 1 (MEN1) syndrome is an autosomal dominant disease characterized by tumors involving parathyroid, pituitary, and pancreas. The diagnosis is mostly clinical and by the presence of MEN1 gene mutation. We present a case with initial presentation of neuroendocrine tumor of pancreas whose ancillary findings on 68 Ga-DOTATATE positron emission tomography-computed tomography helped in raising suspicion of MEN1, which was confirmed on genetic testing and family history. We emphasize the importance of using gestalt approach in such cases to avoid misdiagnosis or delay. Additionally, we describe the clinical profile of affected family members with their MEN1 gene mutation status, highlighting the gestalt approach again to uncover the unknowns.
多发性内分泌肿瘤1型综合征(MEN1)是一种常染色体显性遗传病,以累及甲状旁腺、垂体和胰腺的肿瘤为特征。诊断主要是临床和MEN1基因突变的存在。我们报告一个最初表现为胰腺神经内分泌肿瘤的病例,其68ga - dotatate正电子发射断层扫描-计算机断层扫描的辅助发现有助于提高MEN1的怀疑,并通过基因检测和家族史证实。我们强调在这种情况下使用格式塔方法的重要性,以避免误诊或延误。此外,我们描述了具有MEN1基因突变状态的受影响家庭成员的临床概况,再次强调格式塔方法以揭示未知因素。
{"title":"Familial MEN1 Syndrome Diagnosed on Functional Imaging: A Case Report with Clinical and Genetic Correlation","authors":"Ashwini Kalshetty, Ashwini Chalikandy","doi":"10.1055/s-0043-1768448","DOIUrl":"https://doi.org/10.1055/s-0043-1768448","url":null,"abstract":"Abstract Multiple endocrine neoplasia, type 1 (MEN1) syndrome is an autosomal dominant disease characterized by tumors involving parathyroid, pituitary, and pancreas. The diagnosis is mostly clinical and by the presence of MEN1 gene mutation. We present a case with initial presentation of neuroendocrine tumor of pancreas whose ancillary findings on 68 Ga-DOTATATE positron emission tomography-computed tomography helped in raising suspicion of MEN1, which was confirmed on genetic testing and family history. We emphasize the importance of using gestalt approach in such cases to avoid misdiagnosis or delay. Additionally, we describe the clinical profile of affected family members with their MEN1 gene mutation status, highlighting the gestalt approach again to uncover the unknowns.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138602935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice. 发展中国家的Theranostics:应对从培训到实践的挑战和潜力。
IF 0.6 Pub Date : 2023-09-20 eCollection Date: 2023-09-01 DOI: 10.1055/s-0043-1774733
Akram Al-Ibraheem
In recent times, nuclear medicine (NM) has witnessed noteworthy expansion, presenting several technologies and procedures that aid in the identification and management of various illnesses and disorders. The current era of globalization has posed difficulties for health care systems in managing the escalating incidence of noncommunicable diseases (NCDs) in developing countries.1 The use of radionuclide pairs for both diagnosis and treatment, known as theranostics, has become increasingly popular in developing countries.2 This is due to the availability of more resources, expertise, and personnel. Although the idea of combining therapyand diagnosis has been studied and utilized formany years, recent advancements in cancer genomics and hallmarks have led to significant progress in the field of theranostics over the past two decades. Nowadays, NM theranostics are improving the prognosis of cancer patients through the use of lutetium-based radionuclide therapies, whichhavebeenvalidated in phase III clinical trialswith high confidence.3,4 To date, many Southeast Asian, Middle Eastern, and Latin American countries have continuously offered advanced NM services.5–7 Some of these countries serve as exemplary models in the developing world, as they leverage their limited resources to generate numerous radionuclides, conduct practical research projects, and significantly contribute to the progress of theranostics. Additionally, they have augmented the size of their NM workforce by offering specialized NM training programs as well as fellowship programs. Although theranostics has made substantial strides and improvements, a discernible discrepancy persists among developing countries. This disparity is particularly noticeable in theMiddle East, where numerous countries are embroiled inwars and conflicts.8 These developing countries are currently encountering difficulties keeping up with the latest advancements in theranostics. Presently, there are over 2,000 NM centers in the region.9 Several countries in the region have made investments in establishing production facilities. This investment has contributed to a noticeable increase in the local supply of essential radiopharmaceuticals. It is noteworthy that several centers of excellence in NM are currently involved in providing early experience with innovative theranostic agents, despite several limitations. This has been made possible due to flexible national and institutional regulations that have facilitated the early adoption ofmany novel theranostic pairs. A notable example of this was the recent publication of the first-inhuman single photon emission computed tomography /computed tomography of terbium-prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer by the King Hussein Cancer Center team.10,11 In many developing countries, NM specialists are often perceived by other specialties as diagnostic physicians. This perception remains prominent in regions where the i
{"title":"Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice.","authors":"Akram Al-Ibraheem","doi":"10.1055/s-0043-1774733","DOIUrl":"https://doi.org/10.1055/s-0043-1774733","url":null,"abstract":"In recent times, nuclear medicine (NM) has witnessed noteworthy expansion, presenting several technologies and procedures that aid in the identification and management of various illnesses and disorders. The current era of globalization has posed difficulties for health care systems in managing the escalating incidence of noncommunicable diseases (NCDs) in developing countries.1 The use of radionuclide pairs for both diagnosis and treatment, known as theranostics, has become increasingly popular in developing countries.2 This is due to the availability of more resources, expertise, and personnel. Although the idea of combining therapyand diagnosis has been studied and utilized formany years, recent advancements in cancer genomics and hallmarks have led to significant progress in the field of theranostics over the past two decades. Nowadays, NM theranostics are improving the prognosis of cancer patients through the use of lutetium-based radionuclide therapies, whichhavebeenvalidated in phase III clinical trialswith high confidence.3,4 To date, many Southeast Asian, Middle Eastern, and Latin American countries have continuously offered advanced NM services.5–7 Some of these countries serve as exemplary models in the developing world, as they leverage their limited resources to generate numerous radionuclides, conduct practical research projects, and significantly contribute to the progress of theranostics. Additionally, they have augmented the size of their NM workforce by offering specialized NM training programs as well as fellowship programs. Although theranostics has made substantial strides and improvements, a discernible discrepancy persists among developing countries. This disparity is particularly noticeable in theMiddle East, where numerous countries are embroiled inwars and conflicts.8 These developing countries are currently encountering difficulties keeping up with the latest advancements in theranostics. Presently, there are over 2,000 NM centers in the region.9 Several countries in the region have made investments in establishing production facilities. This investment has contributed to a noticeable increase in the local supply of essential radiopharmaceuticals. It is noteworthy that several centers of excellence in NM are currently involved in providing early experience with innovative theranostic agents, despite several limitations. This has been made possible due to flexible national and institutional regulations that have facilitated the early adoption ofmany novel theranostic pairs. A notable example of this was the recent publication of the first-inhuman single photon emission computed tomography /computed tomography of terbium-prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer by the King Hussein Cancer Center team.10,11 In many developing countries, NM specialists are often perceived by other specialties as diagnostic physicians. This perception remains prominent in regions where the i","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49682940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Journal of Nuclear Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1